← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Colony stimulating factors
filgrastim
L03AA02
Forms & Strengths
- injection: 300 mcg/mL, 480 mcg/1.6 mL
- prefilled syringe: 300 mcg/0.5 mL, 480 mcg/0.8 mL
Adult Dosing
- chemotherapy-induced neutropenia: 5 mcg/kg/day
- bone marrow transplantation: 10 mcg/kg/day
- peripheral blood progenitor cell collection: 10 mcg/kg/day
Pediatric Dosing
- chemotherapy-induced neutropenia: 5 mcg/kg/day for patients with cancer
- severe chronic neutropenia: 5-10 mcg/kg/day
Indications
- prevention of chemotherapy-induced neutropenia
- reduction of neutropenia-related infections in cancer patients
- treatment of severe chronic neutropenia
- mobilization of peripheral blood progenitor cells
Mechanism of Action
- stimulates production of neutrophils by binding to G-CSF receptors on precursor cells
- increases neutrophil count by promoting maturation and release of neutrophils
Contraindications
- hypersensitivity to filgrastim or excipients
- allergic-type reactions to E. coli-derived proteins
Adverse Reactions
- bone pain
- musculoskeletal pain
- headache
- fatigue
- sickle cell crisis
- splenic rupture
- leukocytosis
- thrombocytopenia
Drug Interactions
- lithium: may potentiate neutrophil increase
- chemotherapeutic agents: may have additive or synergistic effects on bone marrow
Curated Content: Needs Vetting Before Put to Clinical Use